Nicotinamide Riboside in LVAD Recipients

Sponsor: University of Washington
Collaborator: American Heart Association

Purpose

To obtain feasibility data for a planned, larger study testing the hypothesis that oral NR supplementation will increase myocardial NAD+ levels and improve cardiomyocyte mitochondrial function in participants with advanced heart failure planned for elective left ventricular assist device (LVAD) implantation.

Study Design

Non-randomized, sequential assignment, single blind

Dose

Day 1: 250mg 2x daily, day 2: 500mg 2x daily
Day 3: 1000mg 2x daily
Day 4-14: 1000mg 2x daily (day before surgery)

Length of Intervention

5-14 days

Status

Completed

Condition or Disease 

Heart Failure, Congestive
Heart Failure New York Heart Association Class IV
Mitochondrial Alteration

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Pharmacokinetic/Safety, CompletedANAD StaffPublished